Gene · 51441
Papers3,768
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
241 to 260 of 3,768
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Co-profiling of in situ RNA-protein interactions and transcriptome in single cells and tissues. | Nat Methods | 2025 | 40784921 | PubTator, text mining | PubMed |
| FTO-Mediated m6A Demethylation of CCL2 Promotes Gastric Cancer Progression via Autophagy and Oxidative Stress Regulation. | Dig Dis Sci | 2025 | 40762760 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| Nanoparticle-Delivered siRNA Targeting NSUN4 Relieves Systemic Lupus Erythematosus through Declining Mitophagy-Mediated CD8+T Cell Exhaustion. | MedComm (2020) | 2025 | 40761479 | PubTator, text mining | PubMed |
| Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. | Eur J Med Res | 2025 | 40760677 | PubTator, text mining | PubMed |
| FTO-mediated the destabilization of RASGRF1 mRNA impedes thyroid cancer progression and suppresses macrophage M2 polarization. | Cell Biol Toxicol | 2025 | 40760370 | PubTator, text mining | PubMed |
| KIAA1429-mediated ZFPM2-AS1 m6A modification promotes the proliferation, migration and invasion of osteosarcoma cells. | Oncol Lett | 2025 | 40747381 | PubTator, text mining | PubMed |
| The role of epigenetics in pulmonary fibrosis: recent advances in mechanistic insights and therapeutic implications. | Front Mol Biosci | 2025 | 40746422 | PubTator, text mining | PubMed |
| Inhibition of miR-615-3p enhances dentinogenesis in scaps via PVT1-mediated mitochondrial regulation. | Stem Cell Res Ther | 2025 | 40745571 | PubTator, text mining | PubMed |
| Comprehensive Analysis of N6-Methyladenosine (m6A) RNA Methylation Regulators in Soft Tissue Leiomyosarcoma. | Lab Invest | 2025 | 40744224 | PubTator, text mining | PubMed |
| M6A RNA modification: focusing on non-small cell lung cancer progression, therapeutic strategies and challenges. | Front Oncol | 2025 | 40740874 | PubTator, text mining | PubMed |
| The complex role and molecular mechanism of family with sequence similarity genes in cancer: a comprehensive review. | Discov Oncol | 2025 | 40736938 | PubTator, text mining | PubMed |
| New Diagnostic and Therapeutic Targets for Spinal Cord Injury: GRN Gene. | J Cell Mol Med | 2025 | 40736401 | PubTator, text mining | PubMed |
| Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer. | Front Immunol | 2025 | 40735323 | PubTator, text mining | PubMed |
| RNA m6A modification: a key regulator in normal and malignant processes. | Cell Investig | 2025 | 40734692 | PubTator, text mining | PubMed |
| NSUN5 accelerates the progression of liver hepatocellular carcinoma by m5C-EFNA3-mediated glycolysis. | BMC Cancer | 2025 | 40730949 | PubTator, text mining | PubMed |
| METTL14 Promotes HK-2 Cell Injury in Diabetic Nephropathy Through the Regulation of THBS2 Expression in an m6A-YTHDF2-Dependent Manner. | Exp Clin Endocrinol Diabetes | 2025 | 40730238 | PubTator, text mining | PubMed |
| YTHDF2 alleviates the radioresistance of rectal cancer cells by targeting methylated MYC. | J Radiat Res | 2025 | 40716096 | PubTator, text mining | PubMed |
| Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer. | Elife | 2025 | 40704992 | PubTator, text mining | PubMed |
| Effect of YTH Domain Family Protein 2 on the Sodium Arsenite-Induced Malignant Transformation of Skin Cells. | Zhongguo Yi Xue Ke Xue Yuan Xue Bao | 2025 | 40704464 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51441/papers?page=13